Everybody loves the idea of a new breakthrough drug actually making it to patents. Craig Tendler has directly helped make it happen 30 times, during his tenure at Johnson & Johnson, where he was Global Head and Vice President, Late Stage Clinical Development and Medical Affairs, for Oncology, Hematology and Supportive Care. These global regulatory approvals spanned lung cancer, prostate cancer, bladder cancer and hematologic malignancies. Craig was instrumental in achieving 13 breakthrough designations by the FDA for investigational oncology drugs. On top, Craig, led clinical diligence teams, consummating J&J partnerships with or acquisitions of Cougar Biotechnology (ZYTIGA), Aragon Pharmaceuticals (ERLEADA), Pharmacyclics (IMBRUVICA), Genmab (DARZALEX), and TARIS Biomedical (INLEXZO). Now he is advising the leadership of multiple leading-edge biotech firms and life science investors.

On an alternate career path, Craig was the sports editor of his college newspaper at Cornell. So today, when he is not reachable and the Olympics are on, you know where to find him. Just get on a plane.